Liamid 2.5mg Tablets
Out of date information, search anotherSUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Glibenclamide 2.5mg Tablets BP,
Liamid 2.5mg Tablets,
Gliken 2.5mg Tablets
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains Glibenclamide 2.5mg.
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Tablet for oral use
Glibenclamide 2.5mg Tablets are white, circular tablets marked ‘GL 2.5’ on one face and plain on the reverse.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
Glibenclamide is a hypoglycaemic agent indicated in the treatment of noninsulin dependent diabetes in patients who respond inadequately to dietary measures alone.
4.2 Posology and Method of Administration For oral administration.
Treatment of previously untreated diabetes:
Stabilisation can be started with one 5mg tablet daily with or immediately after breakfast or the first main meal. If control is satisfactory one tablet is continued as the maintenance dose. If control is unsatisfactory, the dose can be adjusted by increments of 2.5 or 5mg at weekly intervals. The total daily dosage rarely exceeds 15mg and increasing the daily dosage above this does not generally produce any additional effect.
The total daily requirement should normally be given as a single dose at breakfast, or with the first main meal. The patient’s diet and activity should be taken into account.
Children: Glibenclamide is not recommended for use in children.
Elderly: In debilitated patients or aged patients who may be more liable to hypoglycaemia, treatment should be initiated with one 2.5mg tablet daily.
Changeover from other sulphonylureas:
The changeover to glibenclamide from other drugs with similar mode of action can be carried out without any break in therapy.
Treatment is commenced with the equivalent dose of glibenclamide without exceeding an initial dose of 10mg. If response is inadequate, the dose can be raised in a stepwise fashion to 15mg daily. One 5mg tablet of glibenclamide is approximately equivalent to 1g tolbutamine or glymidine, 250mg chlorpropamide or tolazamide, 500mg acetohexamide, 25mg glibornuride or 5mg glipizide.
Changeover from biguanides: The biguanide should be withdrawn and glibenclamide treatment started with one 2.5mg tablet. The dosage should then be adjusted by increments of 2.5mg to achieve control.
Combination with biguanides: If adequate control is not possible with diet and 15mg of glibenclamide, control may be established by combined administration of glibenclamide and a biguanide derivative.
Changeover from insulin:
While it is appreciated that most patients who are on insulin therapy will continue to need it, there may be a few patients, particularly those on low daily doses, who will remain stabilised if transferred from insulin to glibenclamide.
4.3 Contraindications
Glibenclamide should not be used in the following groups:
i) Those patients who have or have ever had diabetic ketoacidosis or diabetic coma/precoma.
ii) Insulin dependent diabetes mellitus.
iii) Severe impairment of renal, hepatic, thyroid or adrenocortical function.
iv) Circumstances of unusual stress such as surgery, severe infection and trauma.
v) Hypersensitivity to glibenclamide or to any of the excipients
vi) 'Brittle' or juvenile diabetes.
vii) Pregnancy
viii) Breast feeding women.
ix) In patients treated with bosentan.
4.4 Special Warnings and Precautions for Use
Patients with rare hereditary problems of galactose intolerance, the Lapp
lactase deficiency or glucose galactose malabsorption should not take this
medicine.
Care is necessary in the following patients:
• Elderly, debilitated or malnourished patients who are particularly susceptible to the hypoglycaemic effects of sulphonylureas,
• During excessive exercise as hypoglycaemia may be provoked.
• Patients with mild to moderate renal impairment. In long-term clinical trials patients with renal insufficiency have been treated satisfactorily using glibenclamide at reduced doses with careful patient monitoring.
• patients with adrenal or pituitary insufficiency
4.5 Interaction with other medicinal products and other forms of Interaction
Bosentan: An increased incidence of elevated liver enzymes was observed in patients receiving glibenclamide concomitantly with bosentan.
Both glibenclamide and bosentan inhibit the bile salt export pump, leading to intracellular accumulation of cytotoxic bile salts. Therefore this combination should not be used.
The hypoglycaemic effect of glibenclamide may be increased by: antiinfective agents (eg: chloramphenicol, fluconazole, miconazole, sulphonamides including co-trimoxazole), anti-inflammatory/analgesic agents (e.g.: phenylbutazone, salicylates), dicoumarin anticoagulants and heparin, lipid regulating agents (e.g. clofibrate), some antidepressants (monoamine oxidase inhibitors, doxepin, nortriptyline), ACE-inhibitors captopril, enalapril, H2-blockers, cimetidine, ranitidine, fenfluramine, methyldopa and sulphinpyrazone, necessitating dosage reduction.
The hypoglycaemic effect of glibenclamide may be diminished by rifampicin, thiazide diuretics and beta-blockers, necessitating dosage increase. Betablockers may mask some of the symptoms of hypoglycaemia. Alcohol may interact with the sulphonylureas, provoking facial flushing, and has a variable effect on blood sugar levels.
Glibenclamide may either potentiate or weaken the effect of coumarin derivatives.
Immunosuppressants: there is the potential for glibenclamide to raise plasma levels of ciclosporin.which would necessitate a dose reduction of ciclosporin.
4.6 Pregnancy and lactation
There is no specific information on glibenclamide in pregnancy - insulin therapy is usually substituted.
Glibenclamide may be secreted in breast milk and caution should be exercised when prescribing for nursing mothers, as there is a possibility of causing hypoglycaemia in the infant.
4.7 Effects on Ability to Drive and Use Machines
Alertness and reactions may be impaired by hypo-or hyperglycaemic episodes, especially when beginning or after altering treatment, or when Glibenclamide is not taken regularly. This may affect the ability to drive or operate machinery.
4.8 Undesirable Effects
Blood disorders
Potentially life-threatening changes in the blood picture may occur. They may include - rarely - mild to severe, thrombocytopenia (e.g. presenting as purpura), - isolated cases - leucopenia, agranulocytosis and (e.g. due to myelosupression)pancytopenia, haemolytic anaemia, erythrocytopenia, granulocytopenia.
Immune system disorders
Hypersensitivity including dyspnoea and swelling of the lips, face, throat or tongue.
Endocrine disorders
Infrequently a syndrome of inappropriate secretion of antidiuretic hormone may be induced which may give rise to reduced serum sodium levels.
Metabolism and nutritional disorders:
Hypoglycaemia
Hypoglycaemia, sometimes prolonged and even life-threatening, may occur as a result of the blood glucose lowering action of Glibenclamide. Possible symptoms of hypoglycaemia include headache, ravenous hunger, nausea, vomiting, lassitude, sleepiness, disordered sleep, restlessness, aggressiveness, impaired concentration, alertness, and reactions, depression, confusion, speech disorders, aphasia, visual disorders, tremor, pareses, sensory disturbances, dizziness, helplessness, loss of self control, delirium, cerebral convulsions, somnolence and loss of consciousness up to and including coma, shallow respiration and bradycardia.
Signs of adrenergic counter-regulation may be present such as sweating, clammy skin, anxiety, tachycardia, hypertension, palpitations, angina pectoris and cardiac arrhythmias.
The clinical picture of a severe hypoglycaemic attack may resemble that of a stroke. The symptoms of hypoglycaemia nearly always subside when hypoglycaemia is corrected.
Eye disorders
Temporary visual impairment.
Gastrointestinal disorders
Gastrointestinal symptoms such as nausea, vomiting, sensations of pressure or fullness in the epigastrium, abdominal pain, diarrhoea may occur.
Hepatobiliary disorders
In isolated cases, there may be elevation of liver enzyme levels and even impairment of liver function (e.g. with cholestatic jaundice and hepatitis which can regress after withdrawal of Glibenclamide, although they may lead to life-threatening liver failure.)
Skin and subcutaneous tissue disorders
Occasionally, allergic or pseudoallergic reactions may occur, e.g. in the form of itching or rashes.
In isolated cases, photosensitivity may occur, and mild reactions in the form of urticaria may develop into serious and even life-threatening reactions.
Hypersensitivity reactions can occur, they consist mainly of allergic skin reactions which progress rarely to erythema multiforme, Stevens-Johnson syndrome, erythema nodosum and exfoliative dermatitis, fever and jaundice.
4.9 Overdose
In acute poisoning activated charcoal may be considered. Hypoglycaemia should be treated urgently in the conscious patient with oral glucose.
If the patient is comatose, glucose should be administered as an intravenous infusion. Alternatively glucagon, administered in a dose of 1mg subcutaneously or intramuscularly may be used. The patient should be observed over several days in case hypoglycaemia recurs.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Pharmacotherapeutic Group: Sulfonamides, Urea derivatives- ATC code: A10BB01
Glibenclamide is an orally active hypoglycaemic agent which acts by stimulating insulin secretion.
5.2 Pharmacokinetic Properties
Glibenclamide is rapidly absorbed and is extensively bound to plasma proteins, but is not readily displaced by acidic drugs. The drug is metabolised extensively in the liver and excreted as metabolites in the urine and bile.
5.3 Preclinical safety data
There are no pre-clinical data of any relevance to the prescriber, which are additional to those already included in other sections.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Lactose monohydrate
Maize Starch Povidone K30 Magnesium stearate
6.2 Incompatibilities
None
6.3 Shelf life
36 months
6.4 Special precautions for storage
Polyethylene/polypropylene and glass containers: Do not store above 25° C. Store in the original container. Keep the container tightly closed.
Blister strips: Do not store above 25° C. Store in the original container. Keep in the outer carton.
6.5 Nature and Contents of Container
Polypropylene or polyethylene tablet container with polypropylene or polyethylene tamper evident closure containing 100, 500 or 1000 tablets
Glass container with plastic tamper evident closure containing 100, 500 or 1000 tablets.
White opaque blister (250pm UPVC 40gsm UPVDC) sealed with 20pm tempered aluminium foil. Tablets are packed in multiples of strips of 10, 14 or 28 tablets.
Not all pack sizes may be marketed.
6.6 Special precautions for disposal
None
7 MARKETING AUTHORISATION HOLDER
Aurobindo Pharma Limited Ares,
Odyssey Business Park,
West End Road,
South Ruislip HA4 6QD,
United Kingdom
MARKETING AUTHORISATION NUMBER(S)
PL 20532/0079
9
10
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
14/12/1989 / 20/02/2009
DATE OF REVISION OF THE TEXT
04/07/2011